DoxorubicinAntibiotics, AntineoplasticInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsTaxoidsAntineoplastic AgentsCisplatinCombined Modality TherapyCell Line, TumorChemotherapy, AdjuvantDrug Resistance, NeoplasmTreatment OutcomeRemission InductionApoptosisPaclitaxelBreast NeoplasmsCaspase 12Disease-Free SurvivalCyclophosphamideTumor Suppressor Protein p53Survival AnalysisNeoplasm StagingDrug Administration ScheduleSurvival RateNeoadjuvant TherapyLung NeoplasmsEtoposideFluorouracilHead and Neck NeoplasmsCarcinoma, Squamous CellAntineoplastic Agents, PhytogenicVincristinePrognosisCardiomyopathiesCytarabineCarboplatinDaunorubicinNeoplasm Recurrence, LocalMitochondria, HeartCarcinoma, Non-Small-Cell LungVinblastineIfosfamideDNA DamageLeukemia, Myeloid, AcuteDeoxycytidineNeoplasm MetastasisTumor Markers, BiologicalAdenocarcinomaRNA, MessengerGene Expression Regulation, NeoplasticRNA, Small InterferingMyocardiumDose-Response Relationship, DrugSignal TransductionHeartRadiotherapy, AdjuvantTime FactorsNeutropeniaMethotrexateFollow-Up StudiesBleomycinChemoradiotherapyKaplan-Meier EstimateRadiotherapyEnzyme InductionTumor BurdenRadiotherapy DosagePrecursor Cell Lymphoblastic Leukemia-LymphomaNeoplasmsMitoxantroneSalvage TherapyGranulocyte Colony-Stimulating FactorInfusions, IntravenousBone NeoplasmsIdarubicinAntimetabolites, AntineoplasticHypopharyngeal NeoplasmsAnthracyclinesLymphatic MetastasisDisease ProgressionTumor Necrosis Factor-alphaProspective StudiesLaryngectomyLeukopeniaTransplantation, AutologousNasopharyngeal NeoplasmsLiver NeoplasmsLeukemia, MyeloidRetrospective StudiesP-GlycoproteinPrednisoneBrain NeoplasmsTesticular NeoplasmsEpirubicinOvarian NeoplasmsAntibodies, MonoclonalOrganoplatinum CompoundsMelphalanStomach NeoplasmsBridged Compounds